Journal of Dietary Supplements最新文献

{"title":"Oral Curcumin for Tendon Health: An Appraisal on Carrier Systems, Bioenhancers, and Synergistic Formulations.","authors":"H N Siti, P L Lua, M N A Taib, M S Zulfarina, M L Nordin, M A Sharifudin","doi":"10.1080/19390211.2026.2662847","DOIUrl":"https://doi.org/10.1080/19390211.2026.2662847","url":null,"abstract":"<p><p>Native curcumin's clinical utility is severely limited by poor solubility and rapid metabolism. While preclinical models demonstrate potent effects on tendon repair, achieving therapeutic concentrations in humans requires advanced formulation strategies. This review aims to reiterate the pharmacokinetic (PK) limitations inherent to native curcumin and critically appraise current oral formulation strategies designed to enhance its bioavailability. It further delineates the role of other adjunct compounds that may or may not be incorporated into curcumin formulations for tendon repair. By synthesizing available human pharmacokinetic data, this review evaluates the clinical potential of curcumin formulations in the management of tendinopathy. Human pharmacokinetic data on current curcumin delivery systems are synthesized. The primary functions of common formulation adjuncts such as piperine, EGCG, bromelain, and boswellia are evaluated for their benefits as bioenhancers or independent therapeutics for tendon health. Clinical outcomes from studies utilizing these combined formulations in tendinopathies are also reviewed. Analysis of dose-normalized PK data confirms that modern formulations significantly improve relative bioavailability compared to native curcumin. However, current evidence suggests that formulation adjuncts contribute primarily through independent biological pathways rather than direct PK bio-enhancement. Clinical evidence suggests these 'multimodal' formulations are associated with accelerated pain reduction, improved functional scores, and reduced non-steroidal antiinflammatory drugs consumption. Tendinopathy management is increasingly moving toward high-efficiency curcumin delivery paired with synergistic co-factors. While enhanced oral formulations show significant clinical association with improved recovery, future research should bridge the gap between plasma levels and direct intratendinous penetration.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"1-22"},"PeriodicalIF":2.3,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147773036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement of Retraction: Taurine supplementation improves functional capacity, myocardial oxygen consumption and electrical activity in heart failure.","authors":"","doi":"10.1080/19390211.2026.2656044","DOIUrl":"https://doi.org/10.1080/19390211.2026.2656044","url":null,"abstract":"","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D Supplementation in Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.","authors":"Dimitrios Papandreou, Salwa Bader, Khaled Abass, Myriam Abboud, Sousana K Papadopoulou, Salah Abusnana","doi":"10.1080/19390211.2026.2636469","DOIUrl":"https://doi.org/10.1080/19390211.2026.2636469","url":null,"abstract":"<p><p>Vitamin D deficiency is prevalent in type 2 diabetes mellitus (T2DM) and may influence metabolic control. The efficacy of supplementation remains contested. This systematic review aimed to evaluate the effect of vitamin D supplementation on primary glycemic outcomes (HbA1c, fasting blood glucose [FBG], HOMA-IR) and secondary metabolic parameters (lipid profile, blood pressure, anthropometrics) in adults with T2DM or prediabetes. This review was conducted according to Cochrane methodology and reported following PRISMA 2020 guidelines. Randomized controlled trials (RCTs) were identified <i>via</i> systematic searches of PubMed, Scopus, and Web of Science up to March 2025. Study selection, data extraction, and risk of bias assessment (using Cochrane RoB 2 tool) were performed in duplicate. A narrative synthesis was performed due to substantial heterogeneity. Thirty RCTs (<i>n</i> = 2627) were included. Studies varied in vitamin D dosage (1,000 to 600,000 IU), duration (8-52 wk), and participant baseline status. Overall, supplementation consistently increased serum 25(OH)D levels. For primary outcomes, significant reductions in HbA1c and FBG were reported in approximately half of the studies, particularly among participants with baseline vitamin D deficiency. Effects on HOMA-IR were mixed. Secondary outcomes (lipids, blood pressure, BMI) showed minimal or inconsistent changes. Vitamin D supplementation may improve glycemic control in individuals with T2DM who are vitamin D deficient, but appears ineffective in those with sufficient levels. It does not consistently improve other metabolic parameters. Targeted supplementation based on individual vitamin D status is recommended, rather than universal administration.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"1-33"},"PeriodicalIF":2.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/19390211.2026.2635318","DOIUrl":"https://doi.org/10.1080/19390211.2026.2635318","url":null,"abstract":"","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"1"},"PeriodicalIF":2.3,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147276213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equol, a Metabolite of Daidzein, Inhibits IgE-Dependent Basophil Activation by Modulating Intracellular Signaling.","authors":"Kouya Yamaki, Mizuki Kawaoka, Ai Nakashima, Akari Matsuda, Mai Takahara, Airi Uchida, Mao Nagaike, Mika Yamano, Yutaka Koyama","doi":"10.1080/19390211.2026.2624111","DOIUrl":"https://doi.org/10.1080/19390211.2026.2624111","url":null,"abstract":"<p><strong>Background: </strong>Currently, the health-promoting effects of equol, an active metabolite of the naturally occurring isoflavone daidzein, in human digestive organs are attracting attention. Although the anti-inflammatory properties of equol have been elucidated and reported, the effect of equol on basophil activation associated with allergy induction has not been clarified.</p><p><strong>Objective: </strong>In this study, we investigated the inhibitory effects of equol on basophil degranulation, which is responsible for anaphylaxis and allergic symptoms.</p><p><strong>Methods: </strong>The rat basophilic leukemia cell line, RBL2H3, was sensitized with anti-ovalbumin IgE and stimulated with ovalbumin in the presence or absence of equol, daidzein, and genistein. β-hexosaminidase and interleukin-4 releases in parallel with phosphorylation of intracellular signaling molecules such as ERK, JNK, p38, and Akt were measured. In addition, the effect of equol on the increase in surface CD63 expression of mouse primary spleen basophils (CD200R3⁺CD49b⁺) was examined following various stimulations including anti-IgE stimulation.</p><p><strong>Results: </strong>Pretreatment of equol for 15 min significantly inhibited β-hexosaminidase at 20 min and interleukin-4 release at 4 h after stimulation without affecting cell viability. The inhibitory effect of equol on cell degranulation was comparable to that of genistein and daidzein. Treatment with equol also diminished the IgE-dependent increase in the phosphorylation levels of Akt, ERK, JNK and p38. Moreover, equol attenuated IgE-dependent mouse primary basophil degranulation, as indicated by increased CD63 expression. Ionomycin- or thapsigargin-induced CD63 expression was also inhibited by the compound.</p><p><strong>Conclusions: </strong>These results suggest that equol might be a potential candidate as an anti-allergic agent as well as related isoflavones.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"1-15"},"PeriodicalIF":2.3,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creatine Supplementation and the Brain: Have We Put the Cart Before the Horse?","authors":"Darren G Candow, Jedd Pratt, Nicholas Fabiano, Ali Gordji-Nejad, Aaron Smith, Eric S Rawson, Terence Moriarty, Scott C Forbes, Chad M Kerksick","doi":"10.1080/19390211.2026.2616440","DOIUrl":"10.1080/19390211.2026.2616440","url":null,"abstract":"<p><p>Creatine is an important regulator of brain bioenergetics, yet the efficacy of creatine supplementation (CrS) in the brain remains largely unknown. Measurement of brain creatine using proton (¹H) and phosphorus (³¹P) magnetic resonance spectroscopy is highly sensitive to voxel placement, signal quality, analysis pipelines, and reporting conventions which can obscure the detection of biological responses to CrS. There is evidence that CrS increases brain creatine, but this response may be dose and/or duration dependent. CrS provides some benefits during acute periods of metabolic stress such as sleep deprivation, mental fatigue, and hypoxia. Emerging clinical data also suggest potential therapeutic effects from CrS for Alzheimer's disease, major depressive disorder, and mild traumatic brain injury (mTBI), although findings across conditions remain preliminary and inconsistent. Further, CrS shows some promise for improving aspects of sleep quality. The purpose of this narrative review is to: (1) outline methodological considerations in the quantification of brain creatine, (2) discuss the divergent effects of CrS on brain creatine levels and measures of brain function, (3) examine the purported mechanistic actions of CrS for improving brain health and function, (4) highlight critical gaps and limitations which should be considered moving forward, and (5) identify future research directions involving CrS and the brain.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"175-204"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioavailability and Metabolism of N-Trans Caffeoyltyramine and N-Trans Feruloyltyramine - A Narrative Review.","authors":"Julie Shlisky, Swati Kalgaonkar, Clayton S Bloszies, Jan-Willem van Kinken, Mario G Ferruzzi","doi":"10.1080/19390211.2025.2597203","DOIUrl":"10.1080/19390211.2025.2597203","url":null,"abstract":"<p><p>Insights into the bioavailability of hemp derived phenolic amides N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT) remained limited to experimental data from preclinical <i>in vitro</i> and animal systems. However, the bioavailability of similar phenolics and phenolic amides from other sources has been experimentally determined. This concise review summarizes the current state of knowledge for phenolic amides with the goal of providing experimental guidance on the assessment of NCT and NFT from hemp ingredients in humans. Evidence from phenolic and avenanthramide (similar phenolic amides from oats) suggest that overall absorption of free phenolic amides would be limited in humans to <2% of native forms. Metabolites derived by both host (conjugated Phase II metabolites) and microbial fermentation products would likely represent the main compounds in circulation derived from NCT or NFT intake. This would be extensively influenced by the matrix provided including hemp-based ingredients with large portions of physically and chemically bound NCT and NFT forms that are not absorbable. Experimental designs to determine NCT and NFT response in humans would need to consider longer exposure and collection periods to adequately capture 24 and 48h urine and blood samples likely to have key NCT and NFT derived microbial and host metabolites present. Considering adaptation of the microbiota to these compounds it is likely that a robust design would also include a dimension of long-term exposure to enable detection of target metabolites derived from hemp NCT and NFT.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"101-117"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Tart Cherry Extract Supplementation on Plasma Urate and C-Reactive Protein Levels in Healthy Adults: a Randomized Controlled Trial.","authors":"Ralf Jäger, Martin Purpura, Sebastian T Balcombe, Ashok Godavarthi, Suda A Reddy, Ecaterina Vasenina, Grant M Tinsley","doi":"10.1080/19390211.2025.2589787","DOIUrl":"10.1080/19390211.2025.2589787","url":null,"abstract":"<p><p>Tart cherry (<i>Prunus cerasus</i> L.) extracts are plant extracts rich in polyphenolic compounds, particularly anthocyanins, which exhibit antioxidant and anti-inflammatory properties. These bioactives may help reduce plasma urate and C-reactive protein (CRP) levels, supporting cardiovascular and the management of hyperuricemia. Processing and formulation methods can influence tart cherry products stability and efficacy. To evaluate the effects of a standardized tart cherry extract on plasma urate and CRP levels. In a randomized, double-blind, placebo-controlled, crossover trial, 10 healthy subjects (n = 10; 6 male, 4 female, age: 34.9 ± 6.6 years, height: 155.3 ± 2.9 cm, weight: 67.1 ± 5.2 kg) consumed 500 mg of a European tart cherry (<i>Prunus cerasus</i> L.) extract powder or placebo for 4 wk, with a 14-day washout between treatment. Venous blood samples were collected at baseline and at 2-, 4-, and 8-h post-ingestion on day 1, as well as at 8 h post-ingestion on day 28, and were analyzed for plasma urate and CRP concentrations. Acute administration did not alter CRP or urate concentrations. Chronic supplementation significantly reduced CRP by 23.0% (- 1.36 ± 0.44 mg/L) and urate by 37.4% (-2.62 ± 0.44 mg/dL) compared to placebo (both p &lt; 0.001). Four weeks of daily supplementation with 500 mg of tart cherry extract significantly reduced systemic inflammation and urate levels in healthy adults, supporting its potential as a polyphenol-rich, foodbased strategy for managing low-grade inflammation and hyperuricemia.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"42-57"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145540866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guanidinoacetic Acid Supplementation: A Mechanistic Model of Utilization and Clearance.","authors":"Sergej M Ostojic","doi":"10.1080/19390211.2025.2606749","DOIUrl":"10.1080/19390211.2025.2606749","url":null,"abstract":"<p><p>Guanidinoacetic acid, the immediate precursor of creatine, is gaining renewed attention as a nutritional and therapeutic agent capable of enhancing tissue bioenergetics. Yet, a comprehensive mechanistic framework describing how exogenous guanidinoacetic acid is processed in the human body is lacking. This concept paper proposes an integrated metabolic model of guanidinoacetic acid utilization, synthesizing available kinetic evidence on its enzymatic conversion <i>via</i> guanidinoacetate N-methyltransferase (GAMT), cellular trafficking through the creatine transporter (SLC6A8), and ancillary routes including reverse amidinotransferase activity, oxidative degradation, and renal handling. Our modeling reveals that GAMT achieves near-saturation at relatively low guanidinoacetic acid intakes, whereas SLC6A8 transport capacity remains underutilized even at higher systemic guanidinoacetic acid levels due to competitive interactions with creatine. Secondary pathways contribute proportionally less to overall guanidinoacetic acid fate but may assume greater importance in metabolic stress, aging, or creatine-deficiency states. By estimating theoretical distributions of guanidinoacetic acid flux across these pathways for commonly used oral doses (1-4 g/day), this manuscript provides a mechanistic foundation for optimizing guanidinoacetic acid supplementation strategies. The model highlights clinically relevant opportunities-such as enhancing creatine repletion, supporting mitochondrial function, and addressing creatine-deficiency syndromes-while identifying key parameters that require <i>in vivo</i> validation. Collectively, this work aims to guide both basic researchers and clinicians toward a more informed and strategic use of guanidinoacetic acid in human nutrition and health.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"257-267"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial.","authors":"Aya M Shama, Noha A El-Bassiouny, Yasser E Bahnacy, Rehab H Werida","doi":"10.1080/19390211.2025.2601020","DOIUrl":"10.1080/19390211.2025.2601020","url":null,"abstract":"<p><strong>Background: </strong>Ischemic cardiomyopathy (ICM) is caused by oxidative stress, inflammation, and apoptosis. Alpha-lipoic acid (ALA) has antioxidant and anti-inflammatory effects. However, its effects on left ventricular dysfunction and myocardial fibrosis remain unclear.</p><p><strong>Objective: </strong>This study aims to investigate the effects of ALA on cardiac inflammation, fibrosis, and myocardial function as an adjuvant therapy for ICM.</p><p><strong>Methods: </strong>This double-blind, randomized, placebo-controlled, single-center trial enrolled 67 diabetic patients with ICM, who were randomized to receive either ALA 600 mg once daily or placebo for three months, in addition to ICM medications. Both groups were evaluated for tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and some echocardiographic indices before and after treatment.</p><p><strong>Results: </strong>Sixty patients (aged 45-75 years; 70% males) completed the study (ALA group <i>n</i> = 30; placebo group <i>n</i> = 30). After three months, the ALA group exhibited significantly lower levels of TNF-α [443 (326/515) vs. 499 (448/657) pg/ml], CRP [4.5 (4.2/6.1) vs. 11 (6.3/12.1) mg/l], TGF-β1 [161 (104/189) vs. 206 (158/248) pg/ml], and MMP-2 [1450 (1164/1894) vs. 1815 (1339/2133) pg/ml] (<i>p</i> < 0.05) compared to the placebo group. Furthermore, in the ALA group, there was a significant increase in LVEF [36% (34/40) vs. 28% (25/31.8)], whereas LVESD, LVEDD, and LAD were significantly decreased compared to the placebo group [4.7 (3.9/5.8) vs. 5.6 (5.1/5.6) cm; 6.1 ± 0.7 vs. 6.5 ± 0.5 cm; 4.2 (3.9/4.7) vs. 4.8 (4.4/5.1) cm] (<i>p</i> < 0.05), respectively.</p><p><strong>Conclusion: </strong>Adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM. Additionally, our findings suggest that ALA may influence profibrotic signaling.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"1-22"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}